Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA shakes up weight loss market
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list.
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Are Compounded Weight Loss Drugs on Their Way Out?
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and Zepbound.
Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding pharmacies to continue selling cheaper copycat versions—at least for now.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.
How Much Do Weight Loss Drugs Cost with and without Insurance?
Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how much is this going to set me back? Lucky for you, we’ve done our homework.
Drug makers can’t make knockoff weight-loss drugs anymore—and they’re mad
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to the drug makers, writing in bold that the agency "reminds compounders of the legal restrictions on making copies of FDA-approved drugs."
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
FDA to review removal of Eli Lilly weight loss drug from shortage list
The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound,
1d
on MSN
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
scrippsnews
13d
FDA says shortage of popular diabetes, weight-loss drugs resolved
There is no longer a shortage for tirzepatide injection, which is known by popular brand names like Mounjaro and Zepbound.
phillyvoice.com
5d
Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers
Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...
5d
on MSN
WeightWatchers rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'
WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Mounjaro
Zepbound
Feedback